D345 Task 1 Drug Class Mechanism Paper Example

Drug Class Mechanism Paper: Psychostimulants, From Transporter Action to What Clinicians Monitor

Student Name

Leavitt School of Health, Western Governors University

D345: Psychopharmacology for Advanced Psychiatric Mental Health Practice, Task 1

Course Instructor

Month Day, Year

Drug Class Mechanism Paper: Psychostimulants, From Transporter Action to What Clinicians Monitor

The Class

Psychostimulants used in psychiatric practice fall into two families: methylphenidate and its isomer dexmethylphenidate, and the amphetamines, including mixed amphetamine salts, dextroamphetamine and the prodrug lisdexamfetamine. They are first-line medications for attention-deficit/hyperactivity disorder (ADHD) across the lifespan. In a network meta-analysis of 133 double-blind randomized trials, amphetamines and methylphenidate both reduced clinician-rated ADHD symptoms in adults compared with placebo, with amphetamines showing the larger effect but also lower tolerability (Cortese et al., 2018). Both families work by increasing dopamine and norepinephrine signaling in brain circuits that support attention and executive function, but they do it in different ways.

Mechanism: Methylphenidate

Methylphenidate blocks the dopamine transporter and the norepinephrine transporter, the proteins that pull these neurotransmitters back into the presynaptic neuron after release. With reuptake blocked, dopamine and norepinephrine remain in the synapse longer and at higher concentrations, strengthening signaling at postsynaptic receptors (Faraone, 2018). Because methylphenidate works by blocking reuptake, its effect depends on the neuron's own firing: it amplifies signals that are already being released. In the prefrontal cortex, where the norepinephrine transporter also clears much of the dopamine, this increases catecholamine signaling that supports sustained attention and working memory.

Mechanism: Amphetamines

Amphetamines also act at the dopamine and norepinephrine transporters, but as substrates rather than simple blockers. They are carried into the presynaptic neuron by the transporters, where they disrupt the vesicular monoamine transporter 2 that normally packages dopamine into storage vesicles. Dopamine accumulates in the cytoplasm, and amphetamine then causes the transporters to run in reverse, pushing dopamine and norepinephrine out into the synapse independent of neuronal firing. Amphetamine also acts at trace amine-associated receptor 1, which contributes to transporter reversal, and weakly inhibits monoamine oxidase (Faraone, 2018). The result is a larger release of catecholamines than reuptake blockade alone produces, which helps explain both the larger average effect size of amphetamines and their greater adverse-effect burden (Cortese et al., 2018).

Formulations and Onset

Both families come in immediate-release and extended-release forms, and formulation shapes the clinical effect as much as the molecule. Immediate-release forms act within about 30 to 60 minutes and last a few hours, creating peaks and troughs. Extended-release technologies, such as osmotic release, beaded capsules and the prodrug lisdexamfetamine, which must be converted to dextroamphetamine by enzymes in red blood cells, smooth the curve and extend coverage across a school or work day. A slower rise in brain concentration is also thought to lower the reinforcing effect that drives misuse, which is one reason extended-release and prodrug forms are often preferred.

Adverse Effects That Follow From the Pharmacology

Cardiovascular: increased norepinephrine signaling raises heart rate and blood pressure modestly in most patients and more in some. Appetite and weight: catecholamine effects in the hypothalamus reduce appetite, and weight loss or slowed growth in children follows. Sleep: stimulation that persists into the evening delays sleep onset, especially with long-acting forms or late doses. Psychiatric: in susceptible people, higher dopamine activity can worsen anxiety, trigger tics or, rarely, cause psychotic or manic symptoms, particularly at high doses. Misuse and dependence: the same dopamine release in reward pathways that is amplified most by amphetamines creates potential for misuse, and in 2023 the Food and Drug Administration required updated boxed warnings for all prescription stimulants describing the risks of misuse, abuse, addiction and overdose (U.S. Food and Drug Administration [FDA], 2023).

What Clinicians Monitor, and Why

Monitoring follows directly from the mechanism and its effects. Blood pressure and heart rate are measured at baseline and at each dose change and routine visit, because of noradrenergic stimulation, and a cardiac history, including unexplained syncope, chest pain and family history of sudden death, is taken before starting. Weight is tracked at each visit, and height in children, because of appetite suppression. Sleep is reviewed, with dose timing adjusted if onset is delayed. Mood, anxiety, tics and any psychotic symptoms are asked about, especially after increases. For misuse and diversion, clinicians check the state prescription drug monitoring program, count refills, ask about how the medication is stored, and watch for requests for early refills or dose escalation. Because stimulants are Schedule II controlled substances, prescriptions follow federal and state controlled-substance rules, including limits on refills.

Interactions

Stimulants should not be combined with monoamine oxidase inhibitors, or started within 14 days of stopping one, because of the risk of hypertensive crisis. Amphetamine excretion is affected by urine pH: acidifying agents increase elimination and alkalinizing agents slow it. Combining stimulants with other noradrenergic drugs, such as some decongestants, can add to blood pressure and heart rate effects. These interactions are predictable from the class's action on catecholamine systems.

How the Mechanism Shapes Use in Special Populations

The pharmacology also explains why some groups need extra caution. In people with known structural heart disease, arrhythmias or poorly controlled hypertension, the noradrenergic effects that are minor for most patients can matter, so cardiology input is sought before treatment. In people with a history of substance use disorder, the reward-pathway effects raise concern about misuse; clinicians in this situation often favor long-acting or prodrug formulations, closer monitoring or a nonstimulant. In people with bipolar disorder or a history of psychosis, increased dopamine signaling can destabilize mood or perception, so the underlying condition is stabilized first. In older adults, cardiovascular risk and interactions with other medicines are more common, so lower starting doses and more frequent vital-sign checks are reasonable. In each case the decision rests on the same mechanism described above, applied to a person whose systems respond to catecholamines differently.

Summary

Psychostimulants increase dopamine and norepinephrine signaling, methylphenidate by blocking reuptake and amphetamines by reversing transporters and releasing stored neurotransmitter. That mechanism explains their efficacy in ADHD and their common adverse effects: raised heart rate and blood pressure, reduced appetite, delayed sleep, occasional psychiatric effects and potential for misuse. Clinical monitoring, from vital signs and weight to prescription drug monitoring checks, is the practical translation of the pharmacology, and understanding the mechanism is what allows a prescriber to anticipate problems rather than only react to them.

References

Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H.-C., Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727-738. https://doi.org/10.1016/S2215-0366(18)30269-4

Faraone, S. V. (2018). The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neuroscience and Biobehavioral Reviews, 87, 255-270. https://doi.org/10.1016/j.neubiorev.2018.02.001

U.S. Food and Drug Administration. (2023). FDA requiring boxed warning updated to improve safe use of prescription stimulants. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-prescription-stimulants